The best indicator for Healthpeak Properties (DOC)
We backtested 20 indicators across daily, weekly and hourly charts on real Healthpeak Properties (DOC) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
WaveTrend (8/6/4)
On the weekly chart, this is the strongest risk-adjusted edge we found for Healthpeak Properties (DOC) over ~41.2 years — trailing buy-and-hold by 4.9% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | WaveTrend (8/6/4) ✓ | Weekly | 5.5% | 0.4 | -40.2% | 77.4% | 31 | -4.9% |
| 2 | CCI ✓ | Weekly | 4.9% | 0.39 | -41.3% | 79.5% | 39 | -5.4% |
| 3 | EMA 50/200 Cross | Daily | 5.3% | 0.36 | -58.2% | 52.0% | 25 | -5.1% |
| 4 | SMA 50/200 Cross | Daily | 5.3% | 0.35 | -61.2% | 53.3% | 30 | -5.1% |
| 5 | EMA 20/50 Cross | Weekly | 5.1% | 0.35 | -65.7% | 53.3% | 15 | -5.3% |
| 6 | Stochastic ✓ | Weekly | 3.9% | 0.34 | -44.4% | 78.4% | 37 | -6.5% |
| 7 | Bollinger Mean-Reversion ✓ | Weekly | 4.3% | 0.33 | -44.3% | 76.5% | 34 | -6.1% |
| 8 | Holy Grail Confluence ✓ | Daily | 4.5% | 0.32 | -42.4% | 71.9% | 57 | -6.0% |
| 9 | Donchian Midline | Weekly | 4.1% | 0.32 | -55.3% | 54.0% | 124 | -6.3% |
| 10 | Holy Grail Confluence ✓ | Weekly | 5.9% | 0.43 | -40.8% | 90.9% | 11 | -4.5% |
| 11 | EMA 20/50 Cross | Daily | 4.2% | 0.31 | -49.1% | 46.5% | 101 | -6.2% |
| 12 | WaveTrend (8/6/4) ✓ | Daily | 4.5% | 0.31 | -59.1% | 69.5% | 151 | -5.9% |
| 13 | Williams %R ✓ | Weekly | 4.1% | 0.31 | -45.9% | 73.1% | 52 | -6.3% |
| 14 | RSI Trend (>50) | Weekly | 3.7% | 0.3 | -57.3% | 47.5% | 122 | -6.6% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Healthpeak Properties (DOC), WaveTrend (8/6/4) on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.